» Articles » PMID: 28757170

The Deleterious Interplay Between Tumor Epithelia and Stroma in Cholangiocarcinoma

Overview
Publisher Elsevier
Date 2017 Aug 1
PMID 28757170
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Prognosis of cholangiocarcinoma, a devastating liver epithelial malignancy characterized by early invasiveness, remains very dismal, though its incidence has been steadily increasing. Evidence is mounting that in cholangiocarcinoma, tumor epithelial cells establish an intricate web of mutual interactions with multiple stromal components, largely determining the pervasive behavior of the tumor. The main cellular components of the tumor microenvironment (i.e. myofibroblasts, macrophages, lymphatic endothelial cells), which has been recently termed as 'tumor reactive stroma', are recruited and activated by neoplastic cells, and in turn, deleteriously mold tumor behavior by releasing a huge variety of paracrine signals, including cyto/chemokines, growth factors, morphogens and proteinases. An abnormally remodeled and stiff extracellular matrix favors and supports these cell interactions. Although the mechanisms responsible for the generation of tumor reactive stroma are largely uncertain, hypoxia presumably plays a central role. In this review, we will dissect the intimate relationship among the different cell elements cooperating within this complex 'ecosystem', with the ultimate goal to pave the way for a deeper understanding of the mechanisms underlying cholangiocarcinoma aggressiveness, and possibly, to foster the development of innovative, combinatorial therapies aimed at halting tumor progression. This article is part of a Special Issue entitled: Cholangiocytes in Health and Diseaseedited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen.

Citing Articles

Research progress of T cells in cholangiocarcinoma.

Wang Z, Dai Y, Zhou Y, Wang Y, Chen P, Li Y Front Immunol. 2025; 16:1453344.

PMID: 40070825 PMC: 11893616. DOI: 10.3389/fimmu.2025.1453344.


Tumor microenvironment and immunology of cholangiocarcinoma.

Cadamuro M, Fabris L, Zhang X, Strazzabosco M Hepatoma Res. 2024; 8.

PMID: 39301518 PMC: 11412615. DOI: 10.20517/2394-5079.2021.140.


The Tumor Immune Microenvironment plays a Key Role in Driving the Progression of Cholangiocarcinoma.

Zhang Y, Yan H, Wu J Curr Cancer Drug Targets. 2024; 24(7):681-700.

PMID: 38213139 DOI: 10.2174/0115680096267791231115101107.


Cholangiocarcinoma-on-a-chip: A human 3D platform for personalised medicine.

Polidoro M, Ferrari E, Soldani C, Franceschini B, Saladino G, Rosina A JHEP Rep. 2023; 6(1):100910.

PMID: 38074504 PMC: 10698278. DOI: 10.1016/j.jhepr.2023.100910.


Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.

Conci S, Catalano G, Roman D, Zecchetto C, Lucin E, De Bellis M Int J Med Sci. 2023; 20(7):858-869.

PMID: 37324191 PMC: 10266048. DOI: 10.7150/ijms.82008.


References
1.
Park J, Tadlock L, Gores G, Patel T . Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology. 1999; 30(5):1128-33. DOI: 10.1002/hep.510300522. View

2.
Elenbaas B, Weinberg R . Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res. 2001; 264(1):169-84. DOI: 10.1006/excr.2000.5133. View

3.
Vihinen P, Kahari V . Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 2002; 99(2):157-66. DOI: 10.1002/ijc.10329. View

4.
Kinnman N, Francoz C, Barbu V, Wendum D, Rey C, Hultcrantz R . The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest. 2003; 83(2):163-73. DOI: 10.1097/01.lab.0000054178.01162.e4. View

5.
Aishima S, Taguchi K, Terashi T, Matsuura S, Shimada M, Tsuneyoshi M . Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma. Mod Pathol. 2003; 16(10):1019-27. DOI: 10.1097/01.MP.0000086860.65672.73. View